Avita Medical (ASX:AVH) share price jumps on FDA approval

Avita shares have landed in the green from the market open. Here are the details…

| More on:
A group of science or medical professionals cheering good news in the lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Medical Inc (ASX: AVH) share price is in the green in early afternoon trade. Avita shares are on the move after the company gained regulatory momentum overnight.

Let's discuss further.

A quick refresher on Avita Medical

Avita Medical is a medical technology company that has expertise in regenerative medicine. Its flagship product is the revolutionary Recell system, used to help skin recover from burns.

In addition, Avita is trialling Recell on other domains such as soft tissue reconstruction and paediatric scald injuries.

At the time of writing, Avita Medical has a market capitalisation of $587 million.

What did Avita announce?

In a positive for the Avitia Medical share price, the company has realised some regulatory tailwinds overnight.

To illustrate, in an announcement Avita advised that the US Food and Drug Administration (FDA) approved the company's request to amend its pivotal clinical trial investigating Recell's application in vitiligo lesions.

Vitiligo is an autoimmune condition that results in the loss of pigmentation of skin.

Recall that Avita originally sought the "strategic decision" to amend its formulation "based on data from other research efforts".

Avita's decision effectively restructures and simplifies the study design. Therefore, the company can progress the program "in a timely and cost-effective manner".

Moreover, the program "is on track" and Avita is confident it could have Recell available for vitiligo applications "as early as the second half of calendar year 2023".

In addition, the new "single-arm" study design allows 23 subjects at 15 sites to be evaluated. This is in contrast to the previous, 3-arm study of 84 patients.

Based on "other research efforts" mentioned above, Avita understands the "1:20 expansion ratio" is the best regime in this application as it used the "least amount of donor skin".

Speaking on the release, Avita chief executive Dr Mike Perry said:

The design change allows this program to progress in a timely and cost-effective manner toward bringing a novel therapeutic option to an underserved population. Our ongoing multi-media outreach and clinical and advocacy group referral programs are generating significant interest in the trial.

Avita Medical share price snapshot

The Avita Medical share price has jumped following the announcement, landing in the green in midday trade. To illustrate, Avita shares are now exchanging hands at $4.76 apiece, a 0.85% jump from the open.

The Avita Medical share price has posted a loss of more than 3% this year to date, and 25% in the past 12 months.

These results have lagged the S&P/ASX 200 Index (ASX: XJO)'s return of around 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week for investors this Friday.

Read more »

A young boy points and smiles as he eats fried chicken.
Share Gainers

3 ASX All Ords shares smashing the benchmark this week

Investors are sending these three ASX All Ords shares rocketing 18% to more than 29% this week. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Alliance Aviation, BHP, Boss Energy, and Orthocell shares are racing higher

These shares are ending the week on a positive note. But why?

Read more »

Man with backpack spreading his arms out and soaking in the sun.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing session for investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a nervous hump day session for ASX investors today.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why Collins Foods, DroneShield, Star Entertainment, and Virgin Australia shares are charging higher

These shares are having a good time on hump day. But why?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors enjoyed a strong recovery day this Tuesday.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

CBA shares hit another all-time high. Can they surpass $200 in 2025?

CBA shares have a tailwind pushing up their price that has nothing directly to do with the bank's business performance.

Read more »